Work

Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study

Year: 2025

Type: article

Abstract: INTRODUCTION: This expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID-19-associated cytokine storm in patients eligible for hospitalization (NCT04355793). METHODS: Patients received ruxolitinib 5 mg twice daily (preferred regimen when tolerated) or once daily for ≤ 14 days, or until determination of no clinical benefit was made. Outcomes were clinical status, physician-assessed clinical benefit, and serious adverse event (SAE) incidence. RESULTS: Of 312 patients, 45.5% achieved ≥ 1-point clinical status improvement. Physician-assessed clinical benefit was reported in 42.6% of evaluable patients. SAEs occurred in 42.9%, with 2.6% experiencing an SAE suspected to be ruxolitinib related. CONCLUSIONS: Overall, some hospitalized patients with COVID-19-associated cytokine storm who received ruxolitinib experienced clinical status improvement; ruxolitinib was well tolerated. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04355793.

Source: The Clinical Respiratory Journal

DOI: 10.1111/crj.70050

Authors: Jeffrey Weinstein, Nikhil Jagan, Shawnta Lorthridge‐Jackson, J. E. Hamer‐Maansson, Peg Squier

Institutions: Creighton University, Incyte (United States)

Language: English

Topic: COVID-19 Clinical Research Studies

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,310